His primary scientific interests are in Immunology, Sepsis, Intensive care, Internal medicine and Organ dysfunction. As a part of the same scientific study, he usually deals with the Immunology, concentrating on Tight junction and frequently concerns with Ratón, Pathogenesis, Barrier function and Pathology. His research on Sepsis frequently connects to adjacent areas such as Pharmacology.
His Intensive care research integrates issues from Anesthesia, Cohort study, Anemia and Intensive care unit. Mitchell P. Fink focuses mostly in the field of Internal medicine, narrowing it down to matters related to Endocrinology and, in some cases, Resuscitation and Shock. His research investigates the link between Organ dysfunction and topics such as Clinical trial that cross with problems in Intensive care medicine and Septic shock.
Sepsis, Pharmacology, Immunology, Internal medicine and Biochemistry are his primary areas of study. His Sepsis research incorporates elements of Clinical trial and Intensive care medicine. His study in Intensive care medicine focuses on Intensive care in particular.
His research in Pharmacology focuses on subjects like Ischemia, which are connected to Pathology. The concepts of his Internal medicine study are interwoven with issues in Gastroenterology and Endocrinology. His Biochemistry research includes themes of Molecular biology, Nitric oxide, Cytokine and Cell biology.
Mitchell P. Fink focuses on Pharmacology, Sepsis, Inflammation, Immunology and Internal medicine. His work carried out in the field of Pharmacology brings together such families of science as Malondialdehyde, Critical illness, Peroxisome proliferator, Activator and Acute pancreatitis. Organ dysfunction is the focus of his Sepsis research.
His work deals with themes such as Copolymer, Polystyrene, Polymer, Nitric oxide synthase and Sorbent, which intersect with Inflammation. His study in the fields of Proinflammatory cytokine and Inflammatory response under the domain of Immunology overlaps with other disciplines such as Lepromatous leprosy. His biological study deals with issues like Endocrinology, which deal with fields such as Intestinal mucosa.
The scientist’s investigation covers issues in Pharmacology, Molecular biology, Sepsis, Biochemistry and Lipopolysaccharide. His Pharmacology research integrates issues from Malondialdehyde, Nitric oxide synthase, Inflammation, NF-κB and Acute pancreatitis. As a member of one scientific family, Mitchell P. Fink mostly works in the field of Inflammation, focusing on Adenosine and, on occasion, Proinflammatory cytokine.
His Molecular biology research incorporates elements of Extracellular, IκBα, Receptor, HMGB1 and RAGE. His biological study spans a wide range of topics, including Cardiac surgery, Cardiopulmonary bypass and Ischemia. His research on Endocrinology and Internal medicine is centered around Lipopolysaccharide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Mitchell M. Levy;Mitchell P. Fink;John C. Marshall;Edward Abraham.
Intensive Care Medicine (2003)
The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.
Howard L. Corwin;Andrew Gettinger;Ronald G. Pearl;Mitchell P. Fink.
Critical Care Medicine (2004)
Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.
Fisher Cj;Dhainaut Jf;Opal Sm;Pribble Jp.
JAMA (1994)
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Huan Yang;Mahendar Ochani;Jianhua Li;Xiaoling Qiang.
Proceedings of the National Academy of Sciences of the United States of America (2004)
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion
Allan Tsung;Rohit Sahai;Hiroyuki Tanaka;Atsunori Nakao.
Journal of Experimental Medicine (2005)
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study.
John A. Kellum;Lan Kong;Mitchell P. Fink;Lisa A. Weissfeld.
JAMA Internal Medicine (2007)
Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation
Luis Ulloa;Mahendar Ochani;Huan Yang;Mahira Tanovic.
Proceedings of the National Academy of Sciences of the United States of America (2002)
Laboratory models of sepsis and septic shock
Mitchell P. Fink;Stephen O. Heard.
Journal of Surgical Research (1990)
Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.
Mitchell P. Fink;David R. Snydman;Michael S. Niederman;Kenneth V. Leeper Jr..
Antimicrobial Agents and Chemotherapy (1994)
Efficacy of Recombinant Human Erythropoietin in Critically Ill Patients: A Randomized Controlled Trial
Howard L. Corwin;Andrew Gettinger;Ronald G. Pearl;Mitchell P. Fink.
JAMA (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Pittsburgh
University of Pittsburgh
Université Libre de Bruxelles
Feinstein Institute for Medical Research
University of Pittsburgh
University of Pittsburgh
Feinstein Institute for Medical Research
University of Pittsburgh
McMaster University
University of Pittsburgh
Lero
Verdant Electronics
Nankai University
University of Siena
Lancaster University
University of Manchester
University of South Florida
Swedish University of Agricultural Sciences
Wageningen University & Research
National Institutes of Health
Royal Museum for Central Africa
McMaster University
University of Freiburg
Vanderbilt University
University of California, Berkeley
Loyola University Chicago